- Also known as
- BPC 157 · BPC157 · Body Protection Compound 157 · stable gastric pentadecapeptide
- Class
- Gastric-protein-derived synthetic pentadecapeptide
- Form
- Lyophilised powder, in 10 mg vials and in capsules
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
- Molecular weight
- 1419.5 g/mol
What is BPC-157?
A synthetic pentadecapeptide drawn from a gastric protein, BPC-157 has a backbone of 15 amino acids. Across the literature the same substance turns up under several spellings, among them BPC 157, BPC157 and Body Protection Compound 157. The recorded sequence reads Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 residues), and the molecular weight is 1419.5 g/mol. The published literature spans rat, human and in-vitro enzyme assay work. It has reached people in 3 studies, none of them controlled, so their outcomes cannot be pried apart from everything else that shifted at the same time. We ship it as a lyophilised powder in 10 mg vials and capsules from Canadian stock, for laboratory research. None of this is a medicine, and it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Lee E et al.2024 · Altern Ther Health Med · PMID 39325560 | Human, uncontrolled pilot study (n=12 women with interstitial cystitis), private clinic | 10 mg total, given by injection around the inflamed area of the bladder during cystoscopy | Single procedure; follow-up period not stated in the abstract | Ten of 12 patients reported complete resolution of symptoms and 2 of 12 rated their success at 80% on the Global Response Assessment. No adverse events were reported. The study had no control group. |
| Lee E et al.2021 · Altern Ther Health Med · PMID 34324435 | Human, retrospective chart review with phone survey (n=16, knee pain) | Intra-articular BPC-157 alone (n=12) or with thymosin beta-4 (n=4); amount not stated in the abstract | Most patients surveyed 6 months to 1 year after the injection | Eleven of 12 patients given BPC-157 alone reported significant improvement in knee pain, and 14 of 16 overall reported relief. No specific tools were used to measure function or quality of life. |
| Lee E et al.2025 · Altern Ther Health Med · PMID 40131143 | Human, safety pilot (n=2 adults), private clinic | 10 mg in 250 cc normal saline over one hour on day 1, then 20 mg on day 2 (intravenous) | 3 days | The infusions produced no measurable effects on the tested heart, liver, kidney and thyroid biomarkers or blood glucose, and no side effects were reported. |
| Perovic D et al.2019 · J Orthop Surg Res · PMID 31266512 | Rat, spinal cord compression injury model | 200 or 2 μg/kg, one intraperitoneal injection 10 min after injury | Assessed at 1, 4, 7, 15, 30, 90, 180 and 360 days | All injured rats given BPC-157 showed better tail motor function, no autotomy and resolved spasticity by day 15, with less axon loss, oedema and motoneuron loss on microscopy. |
| Duzel A et al.2017 · World J Gastroenterol · PMID 29358856 | Rat, ischaemic colitis and reperfusion model | 10 μg/kg as a bath (1 mL/rat) on the blood-deprived colon segment | 15 min vessel recording; day 10 in the colon obstruction group | BPC-157 increased vessel presentation and collateral connections, and MDA and NO levels were normal in treated rats. On day 10 the obstructed segments showed almost completely spared mucosa. |
| Zivanovic-Posilovic G et al.2016 · Eur J Pharmacol · PMID 27815173 | Rat, bupivacaine cardiotoxicity model; HEK293 cells | 50 µg/kg, 10 µg/kg, 10 ng/kg or 10 pg/kg intraperitoneal, 30 min before or 1 min after bupivacaine; 1 µM in cells | Not stated in the abstract | BPC-157 largely counteracted bupivacaine-induced arrhythmias, AV block and asystole, and given after QRS prolongation it markedly postponed the fatal outcome. In HEK293 cells it inhibited bupivacaine-induced depolarisation. |
| Jelińska J et al.2026 · Int J Mol Sci · PMID 42278509 | Enzyme assay in vitro (acetylcholinesterase, modified Ellman assay) | Not stated in the abstract | Not applicable (enzyme kinetics) | BPC-157 acted as a reversible competitive acetylcholinesterase inhibitor (Ki = 0.48 mM; IC50 = 2.80 mM), with significantly lower potency than clinically used inhibitors. |
What these studies don't show: None of the human studies listed carries a control arm. Lacking anything to measure against, a true effect cannot be told apart from chance. The cohorts are small and the follow-up brief, so long-term safety is not demonstrated. Laboratory testing confirms identity and purity; it is no proof that the compound does anything.
Every study links to its PubMed record. See all BPC-157 studies in the research library →
BPC-157 price in Canada: 10mg vial
Buy BPC-157 in Canada in a 10mg vial, plus capsules and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $52.00 | $5.20/mg |
Other formats and kits
Is BPC-157 available in Canada?
No BPC-157 product is authorized in Canada; no DIN has ever been issued for it. No regulator here has examined its safety, efficacy or quality. We hold it purely as laboratory research material, not for use in any person or animal. Read more →
Side effects reported in studies
Whatever the studies below recorded about tolerability is carried over here word for word. Human work on this scale cannot build a safety profile. Read more →
BPC-157 FAQ
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide drawn from a gastric protein. The published research covers rat, human and in-vitro enzyme assay work. Borealis Peptides offers it as a lyophilised powder in 10 mg vials and capsules for in-vitro laboratory research. It is no drug, nor is it supplied for use in a person or an animal. Each reference here appears alongside the model it ran in and the result as it was published.
Where can I buy BPC-157 in Canada?
We ship it inside Canada from our own stock, in 10 mg vials. Nothing goes out until HPLC has confirmed identity and purity for that batch. Borealis Peptides takes research orders only and delivers to research and business addresses. Every batch has its own HPLC analysis, linked to the number printed on the vial.
Is BPC-157 legal in Canada?
No BPC-157 product is authorized in Canada; no DIN has ever been issued for it. No regulator here has examined its safety, efficacy or quality. We stock it only as research material for the laboratory, not for any use in a person or an animal. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we read it strictly as a statement of what the material is for, not an authorisation.
How much BPC-157 should I use?
Borealis Peptides provides no dosing, protocols or reconstitution volumes, and will not supply them if asked. In the lab the quantity is dictated by the study design, something a supplier cannot reasonably set. The figures shown here are what particular published studies used within their own models: a record of past work, not a recommendation.
What human evidence is there for BPC-157?
Human work exists, but none of it is controlled. 3 studies involved people, in the form of pilots, case reports or retrospective reviews. Absent a control group, none can prove the compound caused what was seen, and the page states as much next to the table.
How long does BPC-157 keep?
Keep sealed vials at −20 °C, dry and shielded from light. After reconstitution, 2–8 °C. As a dry powder it moves at room temperature and is chilled once it arrives. Light and repeated warming harm it far more than the trip itself.
Does BPC-157 need bacteriostatic water?
The capsules are a dry oral format and take no liquid at all. Only the lyophilised vial comes dry, and that is the single format bacteriostatic water is relevant to. It is sold separately. Every batch has its own HPLC analysis, linked to the number printed on the vial.
How is the purity of BPC-157 confirmed?
HPLC confirms identity and purity for every batch, not just once per product. The certificate names the batch it covers, and that batch number sits on the vial, so any result can be traced back to the exact material behind it. Ask with your order number and we will send it.
How does BPC-157 compare with TB-500 and Wolverine blend (BPC-157 + TB-500)?
They are distinct compounds with distinct bodies of literature, and no ranking is given here. TB-500 and Wolverine blend (BPC-157 + TB-500) have 7 cited studies and 8 cited studies on their page against 7 here. The comparison worth making is between the two study tables and the models that sit behind them.
Why is BPC-157 named in a Health Canada advisory?
Because it was one of the peptides seized from sellers putting unauthorized injectable products online. The advisory addresses material sold for people to inject without authorization. Borealis Peptides keeps to research material for laboratory use and sells nothing for injection or for any use in a person, so it sits squarely where the advisory draws its line.








